Advertisement

Lysosomal Storage Disorders Including Neuronal Ceroid Lipofuscinoses

  • Carla Hollak
  • Matthias Kettwig
  • Lars Schlotawa
  • Robert SteinfeldEmail author
Chapter

Abstract

Metabolic disorders that affect the lysosomal degradation of complex carbohydrates, lipids, and proteins are associated with a wide variety of clinical symptoms. At the severe end of the clinical spectrum, neurological symptoms are common and go along with significant brain pathology. The high abundance of sphingolipids in brain partially explains the major neurodegenerative effect of disturbed sphingolipid breakdown. In fact, sphingolipidoses frequently present with an involvement of the cerebral white matter. Other lysosomal disorders, in particular the neuronal ceroid lipofuscinoses (NCLs), primarily affect the cerebral grey matter. The NCLs share the lysosomal accumulation of autofluorescent storage material (lipofuscin) and often result from the disturbed degradation of hydrophobic proteins. The below table lists lysosomal storage diseases that are associated with neurodegeneration. At the milder end of the clinical spectrum, variable degrees of organ involvement exist, such as renal and cardiac disease in Fabry disease and hepatosplenomegaly with bone symtoms in gaucher disease. Neurological involvement is less prominent in these phenotypes.

References

  1. Abaroa L, Garretto NS et al (2011) Myoclonus and angiokeratomas in adult galactosialidosis. Mov Disord 26(4):756–757PubMedGoogle Scholar
  2. Abrahamov A, Elstein D, Horowitz M et al (1995) A new Gaucher disease variant characterized by progressive calcification of heart valves and unique genotype. Lancet 346(8981):1000–1003PubMedGoogle Scholar
  3. Adams C, Green S (1986) Late-onset hexosaminidase A and hexosaminidase A and B deficiency: family study and review. Dev Med Child Neurol 28(2):236–243PubMedGoogle Scholar
  4. Aerts JM, Hollak CE, van Breemen M, Maas M, Groener JE, Boot RG (2005) Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr Suppl 94(447):43–46; discussion 37–8PubMedGoogle Scholar
  5. Asano N, Ishii S, Kizu H, Ikeda K, Yasuda K, Kato A, Martin OR, Fan JQ (2000) In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 267:4179–4186PubMedGoogle Scholar
  6. Baek RC, Kasperzyk JL et al (2008) N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int 52(6):1125–1133PubMedGoogle Scholar
  7. Baldellou A, Andria G, Campbell PE, Charrow J, Cohen I, Grabowski GA, Harris CH, Kaplan P, McHugh K, Mengel E, Vellodi A (2004) Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 16:67–75Google Scholar
  8. Balreira A, Gaspar P, Caiola D, Chaves J, Beirao I, Lopes Lima J, Azevedo JE, Sa Miranda MC (2008) A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. Hum Molec Genet 17:2238–2243PubMedGoogle Scholar
  9. Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146(2):77–86PubMedGoogle Scholar
  10. Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease. NEngl J Med 324:1464–1470Google Scholar
  11. Batzios SP, Zafeiriou DI (2012) Developing treatment options for metachromatic leukodystrophy. Mol Genet Metab 105(1):56–63PubMedGoogle Scholar
  12. Beck M, Sieber N et al (1998) Progressive cerebellar ataxia in juvenile GM2-gangliosidosis type Sandhoff. Eur J Pediatr 157(10):866–867PubMedGoogle Scholar
  13. Benjamin ER, Khanna R, Schilling A, Flanagan JJ, Pellegrino LJ, Brignol N, Lun Y, Guillen D, Ranes BE, Frascella M, Soska R, Feng J, Dungan L, Young B, Lockhart DJ, Valenzano KJ (2012) Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther 20(4):717–726. doi: 10.1038/mt.2011.271 PubMedCentralPubMedGoogle Scholar
  14. Berkovic SF, Dibbens LM, Oshlack A, Silver JD, Katerelos M, Vears DF, Lullmann-Rauch R, Blanz J, Zhang KW, Stankovich J, Kalnins RM, Dowling JP et al (2008) Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet 82:673–684PubMedCentralPubMedGoogle Scholar
  15. Beutler E (1988) Gaucher disease. Blood Rev 2(1):59–70, ReviewPubMedGoogle Scholar
  16. Beutler E, Demina A, Laubscher K, Garver P, Gelbart T, Balicki D, Vaughan L (1995) The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis 21(2):86–108PubMedGoogle Scholar
  17. Biffi A, Lucchini G et al (2008) Metachromatic leukodystrophy: an overview of current and prospective treatments. Bone Marrow Transplant 42(Suppl 2):S2–S6PubMedGoogle Scholar
  18. Biffi A, Aubourg P et al (2012) Gene therapy for leukodystrophies. Hum Mol Genet 20(R1):R42–R53Google Scholar
  19. Bonney DK, O'Meara A et al (2010) Successful allogeneic bone marrow transplant for Niemann-Pick disease type C2 is likely to be associated with a severe 'graft versus substrate' effect. J Inherit Metab Dis doi: 10.1007/s10545-010-9060-3Google Scholar
  20. Brady RO, Kanfer JN, Bradley RM, Shapiro D (1966) Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher’s disease. J Clin Invest 45(7):1112–1115PubMedCentralPubMedGoogle Scholar
  21. Cathey SS, Kudo M et al (2008) Molecular order in mucolipidosis II and III nomenclature. Am J Med Genet A 146A(4):512–513PubMedGoogle Scholar
  22. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ (2004) Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 144:112–120PubMedGoogle Scholar
  23. Chaves J, Beirão I, Balreira A, Gaspar P, Caiola D, Sá-Miranda MC, Lima JL (2011) Progressive myoclonus epilepsy with nephropathy C1q due to SCARB2/LIMP-2 deficiency: clinical report of two siblings. Seizure 20(9):738–740PubMedGoogle Scholar
  24. Christomanou H, Aignesberger A, Linke RP (1986) Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro: absence of one of them in a human Gaucher disease variant. Biol Chem Hoppe Seyler 367:879–890PubMedGoogle Scholar
  25. Clarke JT, Mahuran DJ et al (2011) An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab 102(1):6–12PubMedCentralPubMedGoogle Scholar
  26. Cosma MP, Pepe S et al (2003) The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 113(4):445–456PubMedGoogle Scholar
  27. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481–1485PubMedGoogle Scholar
  28. Cox TM, Aerts JMFG, Andria G, Beck M, Bembi B, Chertkoff R, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Pastores G, Rolfs A, Sa Miranda MC, Zimran A (2003) The role of iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type 1 (nonneuronopathic) Gaucher disease: a position statement. J Inher Metab Dis 26:513–526PubMedGoogle Scholar
  29. D’Azzo A, Hoogeveen A et al (1982) Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci U S A 79(15):4535–4539PubMedCentralPubMedGoogle Scholar
  30. Darin N, Kyllerman M et al (2009) Juvenile galactosialidosis with attacks of neuropathic pain and absence of sialyloligosacchariduria. Eur J Paediatr Neurol 13(6):553–555PubMedGoogle Scholar
  31. Das AK, Lu JY et al (2001) Biochemical analysis of mutations in palmitoyl-protein thioesterase causing infantile and late-onset forms of neuronal ceroid lipofuscinosis. Hum Mol Genet 10(13):1431–1439PubMedGoogle Scholar
  32. De Fost M, Out TA, de Wilde FA et al (2008) Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 87(6):439–449PubMedCentralPubMedGoogle Scholar
  33. Desnick RJ, Schuchman EH (2002) Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 3:954–966PubMedGoogle Scholar
  34. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346PubMedGoogle Scholar
  35. Dierks T, Schmidt B et al (2003) Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell 113(4):435–444PubMedGoogle Scholar
  36. Dierks T, Schlotawa L et al (2009) Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim Biophys Acta 1793(4):710–725PubMedGoogle Scholar
  37. Elliot-Smith E, Speak AO et al (2008) Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol Genet Metab 94(2):204–211PubMedGoogle Scholar
  38. Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease. N Engl J Med 345(1):9–16PubMedGoogle Scholar
  39. Escolar ML, Poe MD et al (2005) Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 352(20):2069–2081PubMedGoogle Scholar
  40. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80(3):307–314PubMedGoogle Scholar
  41. Galjart NJ, Gillemans N et al (1988) Expression of cDNA encoding the human “protective protein” associated with lysosomal beta-galactosidase and neuraminidase: homology to yeast proteases. Cell 54(6):755–764PubMedGoogle Scholar
  42. Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30PubMedCentralPubMedGoogle Scholar
  43. Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18(5):1547–1557PubMedGoogle Scholar
  44. Gieselmann V, Krageloh-Mann I (2010) Metachromatic leukodystrophy–an update. Neuropediatrics 41(1):1–6PubMedGoogle Scholar
  45. Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet 372(9645):1263–1271PubMedGoogle Scholar
  46. Grabowski GA, Kacena K, Cole JA et al (2009) Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 11(2):92–100PubMedCentralPubMedGoogle Scholar
  47. Grossi S, Regis S et al (2008) Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: identification and functional characterization of 11 novel ARSA alleles. Hum Mutat 29(11):E220–E230PubMedGoogle Scholar
  48. Hendriksz CJ, Corry PC et al (2004) Juvenile Sandhoff disease – nine new cases and a review of the literature. J Inherit Metab Dis 27(2):241–249PubMedGoogle Scholar
  49. Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH (1997) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96(3):470–476PubMedGoogle Scholar
  50. Hollak C, Maas M, Akkerman E, den Heeten A, Aerts H (2001) Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 27(6):1005–1012PubMedGoogle Scholar
  51. Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, Rosenbloom B, van Dussen L, Tylki-Szymańska A, Weinreb NJ, Zimran A, Cappellini MD (2012) Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years. Br J Haematol 158(4):528–538PubMedGoogle Scholar
  52. Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29(5):567–583, ReviewPubMedGoogle Scholar
  53. Hsu YS, Hwu WL et al (1999) Niemann-Pick disease type C (a cellular cholesterol lipidosis) treated by bone marrow transplantation. Bone Marrow Transplant 24(1):103–107PubMedGoogle Scholar
  54. Hughes DA, Elliott PM, et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153–158Google Scholar
  55. Hwu WL, Chien YH, Lee NC et al (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30(10):1397–1405PubMedCentralPubMedGoogle Scholar
  56. Ishii S (2012) Pharmacological chaperone therapy for Fabry disease. Proc Jpn Acad Ser B Phys Biol Sci 88:18–30Google Scholar
  57. Jain G, Warnock DG (2011) Blood pressure, proteinuria and nephropathy in Fabry disease. Nephron Clin Pract 118(1):c43–c48, Epub 2010 Nov 11PubMedGoogle Scholar
  58. Kasperzyk JL, d’Azzo A et al (2005) Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res 46(4):744–751PubMedGoogle Scholar
  59. Klima H, Klein A et al (1993) Over-expression of a functionally active human GM2-activator protein in Escherichia coli. Biochem J 292(Pt 2):571–576PubMedCentralPubMedGoogle Scholar
  60. Kolter T, Sandhoff K (2006) Sphingolipid metabolism diseases. Biochim Biophys Acta 1758(12):2057–2079PubMedGoogle Scholar
  61. Kolter T, Proia RL et al (2002) Combinatorial ganglioside biosynthesis. J Biol Chem 277(29):25859–25862PubMedGoogle Scholar
  62. Krivit W, Shapiro EG et al (1998) Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl J Med 338(16):1119–1126PubMedGoogle Scholar
  63. Landrieu P, Blanche S et al (1998) Bone marrow transplantation in metachromatic leukodystrophy caused by saposin-B deficiency: a case report with a 3-year follow-up period. J Pediatr 133(1):129–132PubMedGoogle Scholar
  64. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66(4):1589–1595PubMedGoogle Scholar
  65. Lloyd-Evans E, Morgan AJ et al (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 14(11):1247–1255PubMedGoogle Scholar
  66. Lukina E, Watman N, Avila Arreguin E et al (2010) Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: two-year results of a phase 2 study. Blood 116(20):4095–4098PubMedCentralPubMedGoogle Scholar
  67. Maas M, Poll LW, Terk MR (2002) Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol 75(Suppl 1):A13–A24PubMedGoogle Scholar
  68. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775PubMedCentralPubMedGoogle Scholar
  69. Matsuoka K, Tamura T et al (2011) Therapeutic potential of intracerebroventricular replacement of modified human beta-hexosaminidase B for GM2 gangliosidosis. Mol Ther 19(6):1017–1024PubMedCentralPubMedGoogle Scholar
  70. Matthes F, Stroobants S et al (2012) Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age. Hum Mol Genet 21(11):2599–2609PubMedGoogle Scholar
  71. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254PubMedGoogle Scholar
  72. Mikosch P, Hughes D (2010) An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr 160(23–24):609–624PubMedGoogle Scholar
  73. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B (2000) Excellent outcome of renal transplantation in patients with Fabry’s disease. Transplantation 69(11):2337–2339PubMedGoogle Scholar
  74. Pampols T, Pineda M, Giros ML, Ferrer I, Cusi V, Chabas A, Sanmarti FX, Vanier MT, Christomanou H (1999) Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant. Acta Neuropath 97:91–97PubMedGoogle Scholar
  75. Pastores GM, Weinreb NJ, Aerts H et al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41(4 Suppl 5):4–14PubMedGoogle Scholar
  76. Patterson MC, Hendriksz CJ et al (2012) Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 106(3):330–344PubMedGoogle Scholar
  77. Pierre-Louis B, Kumar A, Frishman WH (2009) Fabry disease: cardiac manifestations and therapeutic options. Cardiol Rev 17(1):31–35PubMedGoogle Scholar
  78. Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA, Butters TD, Cox TM, Lachmann RH, Holla KC, Aerts JM, Van Weely S, Hrebice KM, Moyses C, GowI L, GowI D, Zimran A (2001) Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 24:275–290PubMedGoogle Scholar
  79. Poll LW, Maas M, Terk MR, Roca-Espiau M, Bembi B, Ciana G, Weinreb NJ (2002) Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 75(Suppl 1):A25–A36PubMedGoogle Scholar
  80. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151–156PubMedGoogle Scholar
  81. Raas-Rothschild A, Bargal R et al (2004) Genomic organisation of the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis III. J Med Genet 41(4):e52PubMedCentralPubMedGoogle Scholar
  82. Ranta S, Zhang Y et al (1999) The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8. Nat Genet 23:233–6Google Scholar
  83. Ramsubir S, Nonaka T et al (2008) In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol Genet Metab 95(3):133–141PubMedCentralPubMedGoogle Scholar
  84. Reczek D, Schwake M, Schröder J, Hughes H, Blanz J, Jin X, Brondyk W, Van Patten S, Edmunds T, Saftig P (2007) LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131(4):770–783PubMedGoogle Scholar
  85. Ringdén O, Groth CG, Erikson A, Granqvist S, Månsson JE, Sparrelid E (1995) Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplantation 59(6):864–870PubMedGoogle Scholar
  86. Robinson C, Baker N et al (2002) The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. J Inherit Metab Dis 25(8):681–693PubMedGoogle Scholar
  87. Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg FA, Hollak CE, Linthorst GE (2012) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 7(10):e47805PubMedCentralPubMedGoogle Scholar
  88. Saftig S, Braulke T (2005) Tranport of lysosomal enzymes. In: Saftig P (ed) Lysosomes. Springer Science and Business Media, New York, pp 17–26Google Scholar
  89. Schiffmann R, Kopp JB, Austin HA III et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743–2749PubMedGoogle Scholar
  90. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21(2):345–354PubMedGoogle Scholar
  91. Schiffmann R, Fitzgibbon EJ, Harris C et al (2008) Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol 64(5):514–522PubMedCentralPubMedGoogle Scholar
  92. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102–2111PubMedCentralPubMedGoogle Scholar
  93. Schuchman EH (2007) The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis 30(5):654–663PubMedGoogle Scholar
  94. Schulze H, Kolter T et al (2009) Principles of lysosomal membrane degradation: Cellular topology and biochemistry of lysosomal lipid degradation. Biochim Biophys Acta 1793(4):674–683PubMedGoogle Scholar
  95. Scriver CR (2002) The metabolic and molecular bases of inherited diseases. McGraw-Hill, New York/LondonGoogle Scholar
  96. Seo Y, Yang SR et al (2011) Human umbilical cord blood-derived mesenchymal stem cells protect against neuronal cell death and ameliorate motor deficits in Niemann Pick type C1 mice. Cell Transplant 20(7):1033–1047PubMedGoogle Scholar
  97. Shield JP, Stone J et al (2005) Bone marrow transplantation correcting beta-galactosidase activity does not influence neurological outcome in juvenile GM1-gangliosidosis. J Inherit Metab Dis 28(5):797–798PubMedGoogle Scholar
  98. Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40PubMedCentralPubMedGoogle Scholar
  99. Spiegel R, Bach G et al (2005) A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: first report of saposin A deficiency in humans. Mol Genet Metab 84(2):160–166PubMedGoogle Scholar
  100. Steinfeld R, Heim P et al (2002) Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet 112:347–54Google Scholar
  101. Steinfeld R, Steinke HB et al (2004) Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes. Hum Mol Genet 13(20):2483–2491PubMedGoogle Scholar
  102. Steinfeld R, Reinhardt K et al (2006) Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet 78(6):988–998PubMedCentralPubMedGoogle Scholar
  103. Terryn W, Vanholder R, Hemelsoet D, Leroy BP, Van Biesen W, De Schoenmakere G, Wuyts B, Claes K, De Backer J, De Paepe G, Fogo A, Praet M, Poppe B (2013) Questioning the pathogenic role of the GLA p.Ala143Thr “mutation” in Fabry disease: implications for screening studies and ERT. JIMD Reports 8:101–108. doi: 10.1007/8904_2012_167 PubMedCentralPubMedGoogle Scholar
  104. Tiede S, Storch S et al (2005) Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. Nat Med 11(10):1109–1112PubMedGoogle Scholar
  105. Tsuji D, Akeboshi H et al (2011) Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis. Ann Neurol 69(4):691–701PubMedGoogle Scholar
  106. Tylki-Szymanska A, Czartoryska B, Vanier M-T, Poorthuis BJMH, Groener JAE, Lugowska A, Millat G, Vaccaro AM, Jurkiewicz E (2007) Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin Genet 72:538–542PubMedGoogle Scholar
  107. Van Dussen L, Lips P, Everts VE, Bravenboer N, Jansen ID, Groener JE, Maas M, Blokland JA, Aerts JM, Hollak CE (2011) Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease. J Clin Endocrinol Metab 96(7):2194–2205PubMedGoogle Scholar
  108. Vanier MT (2010) Niemann-Pick disease type C. Orphanet J Rare Dis 5:16PubMedCentralPubMedGoogle Scholar
  109. Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin-Histed T, Mengel E, Erikson A, Schiffmann R, European Working Group on Gaucher Disease (2009) Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 32(5):660–664PubMedGoogle Scholar
  110. Vielhaber G, Hurwitz R et al (1996) Biosynthesis, processing, and targeting of sphingolipid activator protein (SAP )precursor in cultured human fibroblasts. Mannose 6-phosphate receptor-independent endocytosis of SAP precursor. J Biol Chem 271(50):32438–32446PubMedGoogle Scholar
  111. Wang RY, Bodamer OA et al (2011) Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 13(5):457–484PubMedGoogle Scholar
  112. Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Marodi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 5(12):2220–2228PubMedCentralPubMedGoogle Scholar
  113. Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119(4):524–529PubMedGoogle Scholar
  114. Wenger DA, Tarby TJ et al (1978) Macular cherry-red spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies. Biochem Biophys Res Commun 82(2):589–595PubMedGoogle Scholar
  115. Wenger DA, Rafi MA et al (2000) Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab 70(1):1–9PubMedGoogle Scholar
  116. Yoshimitsu M, Higuchi K, Ramsubir S, Nonaka T, Rasaiah VI, Siatskas C, Liang SB, Murray GJ, Brady RO, Medin JA (2007) Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther 14(3):256–265PubMedGoogle Scholar
  117. Zhou XY, Morreau H et al (1995) Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells. Genes Dev 9(21):2623–2634PubMedGoogle Scholar
  118. Zimran A (2011) How I, treat Gaucher disease. Review Blood 118(6):1463–1471Google Scholar
  119. Zimran A, Elstein D (2010) Lipid storage diseases. In: Lichtman MA, Kipps T, Seligsohn U, Kaushansky K, Prchal JT (eds) Williams hematology, 8th edn. McGraw-Hill, New York, pp 1065–1071Google Scholar
  120. Zimran A, Altarescu G, Philips M et al (2010) Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 115(23):4651–4656PubMedGoogle Scholar
  121. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Muñoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D (2011) Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118(22):5767–5773PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Carla Hollak
    • 1
  • Matthias Kettwig
    • 2
  • Lars Schlotawa
    • 2
  • Robert Steinfeld
    • 3
    Email author
  1. 1.Division of Endocrinology and Metabolism, Department of Internal Medicine, F5-170Academic Medical Center, University of AmsterdamAmsterdamThe Netherlands
  2. 2.Department of PediatricsUniversity Medical Center GöttingenGöttingenGermany
  3. 3.Department of PediatricsUniversity of GöttingenGöttingenGermany

Personalised recommendations